| GTO ID | GTC0880 |
| Trial ID | ChiCTR2000036247 |
| Disease | Ovarian Cancer |
| Altered gene | MESO |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | MESO CAR-T cells |
| Co-treatment | Anlotinib |
| Generation | 2nd |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | An exploratory clinical study of Anlotinib combined with meso-4-1bb-cd3 ζ - α PD1 car T cells in the treatment of recurrent and refractory ovarian cancer |
| Year | 2020 |
| Country | China |
| Company sponsor | Shanghai Tenth People's Hospital |
| Cohort 1 | |||||||
|
|||||||